{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:44:35Z","timestamp":1787003075715,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001254","name":"Ipsen Fund","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100001254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71756-7","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:03:58Z","timestamp":1775847838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3013-1816","authenticated-orcid":false,"given":"Mauro","family":"Cives","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Della Vittoria Scarpati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-8570","authenticated-orcid":false,"given":"Ottavia","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lauricella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-136X","authenticated-orcid":false,"given":"Alessandra","family":"Bracigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Delrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ragno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Chaoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Della Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabella","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pizzolorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8458-8648","authenticated-orcid":false,"given":"Joana","family":"Sorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Picozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-4015","authenticated-orcid":false,"given":"Gerardo","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3019-354X","authenticated-orcid":false,"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"71756_CR1","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives, M. & Strosberg, J. R. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 68, 471\u2013487 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"71756_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15798","volume":"8","author":"A Dasari","year":"2025","unstructured":"Dasari, A. et al. Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw. Open 8, e2515798 (2025).","journal-title":"JAMA Netw. Open"},{"key":"71756_CR3","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656\u20134663 (2009).","journal-title":"J. Clin. Oncol."},{"key":"71756_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin, M. E. et al. CLARINET investigators. lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224\u2013233 (2014).","journal-title":"N. Engl. J. Med."},{"key":"71756_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao, J. C. et al. RAD001 in advanced neuroendocrine tumours, fourth trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968\u2013977 (2016).","journal-title":"Lancet"},{"key":"71756_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501\u2013513 (2011).","journal-title":"N. Engl. J. Med."},{"key":"71756_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz, P. L. et al. 3rd. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J. Clin. Oncol. 41, 1359\u20131369 (2023).","journal-title":"J. Clin. Oncol."},{"key":"71756_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. NETTER-1 trial investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71756_CR9","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh, S. et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403, 2807\u20132817 (2024).","journal-title":"Lancet"},{"key":"71756_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan, J. A. et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N. Engl. J. Med. 392, 653\u2013665 (2025).","journal-title":"N. Engl. J. Med."},{"key":"71756_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep21141","volume":"6","author":"MY Li","year":"2016","unstructured":"Li, M. Y. et al. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. Sci. Rep. 6, 21141 (2016).","journal-title":"Sci. Rep."},{"key":"71756_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00280-015-2871-z","volume":"76","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Scorsone, K., Woodfield, S. E. & Zage, P. E. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother. Pharm. 76, 977\u2013987 (2015).","journal-title":"Cancer Chemother. Pharm."},{"key":"71756_CR13","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1158\/1078-0432.CCR-22-0985","volume":"28","author":"JJ Noh","year":"2022","unstructured":"Noh, J. J. et al. Anticancer activity of the combination of cabozantinib and temozolomide in uterine sarcoma. Clin. Cancer Res. 28, 3850\u20133861 (2022).","journal-title":"Clin. Cancer Res."},{"key":"71756_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/00001813-200308000-00003","volume":"14","author":"H Kurzen","year":"2003","unstructured":"Kurzen, H., Schmitt, S., N\u00e4her, H. & M\u00f6hler, T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14, 515\u2013522 (2003).","journal-title":"Anticancer Drugs"},{"key":"71756_CR15","first-page":"33","volume":"16","author":"JT Kim","year":"2006","unstructured":"Kim, J. T. et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol. Rep. 16, 33\u201339 (2006).","journal-title":"Oncol. Rep."},{"key":"71756_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cncr.29798","volume":"122","author":"D Schiff","year":"2016","unstructured":"Schiff, D. et al. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer 122, 582\u2013587 (2016).","journal-title":"Cancer"},{"key":"71756_CR17","doi-asserted-by":"crossref","unstructured":"Agulnik, M. et al. A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas. J. Clin. Oncol. 41, 11505 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.11505"},{"key":"71756_CR18","doi-asserted-by":"crossref","unstructured":"Ikeda, S. et al. Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma. J. Clin. Oncol. 33, 5590 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.5590"},{"key":"71756_CR19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","volume":"26","author":"E Grande","year":"2015","unstructured":"Grande, E. et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann. Oncol. 26, 1987\u20131993 (2015).","journal-title":"Ann. Oncol."},{"key":"71756_CR20","doi-asserted-by":"crossref","unstructured":"Garcia-Carbonero, R. et al. A phase II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). J. Clin. Oncol. 39, 360 (2021).","DOI":"10.1200\/JCO.2021.39.3_suppl.360"},{"key":"71756_CR21","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1200\/JCO.20.03368","volume":"39","author":"J Capdevila","year":"2021","unstructured":"Capdevila, J. et al. Lenvatinib in patients with advanced grade \u00bd pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT Trial (GETNE1509). J. Clin. Oncol. 39, 2304\u20132312 (2021).","journal-title":"J. Clin. Oncol."},{"key":"71756_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 1489\u20131499 (2020).","journal-title":"Lancet Oncol."},{"key":"71756_CR23","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 1500\u20131512 (2020).","journal-title":"Lancet Oncol."},{"key":"71756_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/curroncol29020046","volume":"29","author":"T Al-Toubah","year":"2022","unstructured":"Al-Toubah, T., Morse, B. & Strosberg, J. Efficacy of capecitabine and temozolomide in small bowel (midgut) neuroendocrine tumors. Curr. Oncol. 29, 510\u2013515 (2022).","journal-title":"Curr. Oncol."},{"key":"71756_CR25","doi-asserted-by":"publisher","first-page":"102878","DOI":"10.1016\/j.ctrv.2024.102878","volume":"133","author":"P Melhorn","year":"2025","unstructured":"Melhorn, P., Raderer, M. & Kiesewetter, B. Selecting systemic treatment for metastatic neuroendocrine tumors of the lung-current evidence and clinical implications. Cancer Treat. Rev. 133, 102878 (2025).","journal-title":"Cancer Treat. Rev."},{"key":"71756_CR26","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/jcm8081224","volume":"8","author":"S Tafuto","year":"2019","unstructured":"Tafuto, S. et al. Safety and activity of metronomic temozolomide in second-line treatment of advanced neuroendocrine neoplasms. J. Clin. Med. 8, 1224 (2019).","journal-title":"J. Clin. Med."},{"key":"71756_CR27","doi-asserted-by":"publisher","first-page":"103003","DOI":"10.1016\/j.esmoop.2024.103003","volume":"9","author":"C Von Arx","year":"2024","unstructured":"Von Arx, C. et al. A new schedule of one week on\/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial. ESMO Open 9, 103003 (2024).","journal-title":"ESMO Open"},{"key":"71756_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2018.06.002","volume":"432","author":"G Natale","year":"2018","unstructured":"Natale, G. & Bocci, G. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett. 432, 28\u201337 (2018).","journal-title":"Cancer Lett."},{"key":"71756_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu, Z. L., Chen, H. H., Zheng, L. L., Sun, L. P. & Shi, L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct. Target Ther. 8, 198 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"71756_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke, M. H. et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 24, 401\u2013406 (2006).","journal-title":"J. Clin. Oncol."},{"key":"71756_CR31","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1530\/ERC-11-0287","volume":"19","author":"A Koumarianou","year":"2012","unstructured":"Koumarianou, A. et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr. Relat. Cancer 19, L1\u2013L4 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"71756_CR32","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","volume":"30","author":"JA Chan","year":"2012","unstructured":"Chan, J. A. et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 30, 2963\u20132968 (2012).","journal-title":"J. Clin. Oncol."},{"key":"71756_CR33","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/cancers15235688","volume":"15","author":"\u00c7 \u00dcnal","year":"2023","unstructured":"\u00dcnal, \u00c7 & Sa\u011flam, S. Metronomic temozolomide (mTMZ) and bevacizumab\u2014the safe and effective frontier for treating metastatic neuroendocrine tumors (NETs): a single-center experience. Cancers 15, 5688 (2023).","journal-title":"Cancers"},{"key":"71756_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","volume":"17","author":"AJ Templeton","year":"2020","unstructured":"Templeton, A. J., Amir, E. & Tannock, I. F. Informative censoring\u2014a neglected cause of bias in oncology trials. Nat. Rev. Clin. Oncol. 17, 327\u2013328 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"71756_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamaoncol.2022.7842","volume":"9","author":"BW Labadie","year":"2023","unstructured":"Labadie, B. W. & Fojo, A. T. Requirements for meaningful progress in the therapy of neuroendocrine cancers. JAMA Oncol. 9, 606\u2013608 (2023).","journal-title":"JAMA Oncol."},{"key":"71756_CR36","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1200\/JCO.23.02724","volume":"43","author":"T Walter","year":"2025","unstructured":"Walter, T. et al. \u201cGroupe d\u2019\u00e9tude des tumeurs endocrines (GTE)\u201d and the French ENDOCAN-RENATEN network. Oxaliplatin-based versus alkylating agent in neuroendocrine tumors according to the o6-methylguanine-DNA methyltransferase status: a randomized phase II study (MGMT-NET). J. Clin. Oncol. 43, 960\u2013971 (2025).","journal-title":"J. Clin. Oncol."},{"key":"71756_CR37","doi-asserted-by":"publisher","first-page":"bvaf147","DOI":"10.1210\/jendso\/bvaf147","volume":"9","author":"R Ghosh","year":"2025","unstructured":"Ghosh, R. et al. MEN1-related neuroendocrine tumors show c-MET overexpression. J. Endocr. Soc. 9, bvaf147 (2025).","journal-title":"J. Endocr. Soc."},{"key":"71756_CR38","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1158\/1078-0432.CCR-04-0285","volume":"10","author":"DE Hansel","year":"2004","unstructured":"Hansel, D. E. et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin. Cancer Res. 10, 6152\u20136158 (2004).","journal-title":"Clin. Cancer Res."},{"key":"71756_CR39","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.5858\/2009-0664-OAR1.1","volume":"134","author":"J Song","year":"2010","unstructured":"Song, J. et al. Expression patterns of PAX5, c-met and paxillin in neuroendocrine tumors of the lung. Arch. Pathol. Lab. Med. 134, 1702\u20131705 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"71756_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/hupa.2003.56","volume":"34","author":"S La Rosa","year":"2003","unstructured":"La Rosa, S. et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol. 34, 18\u201327 (2003).","journal-title":"Hum. Pathol."},{"key":"71756_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000487237","volume":"107","author":"A Pellat","year":"2018","unstructured":"Pellat, A. et al. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology 107, 24\u201331 (2018).","journal-title":"Neuroendocrinology"},{"key":"71756_CR42","doi-asserted-by":"publisher","first-page":"A323","DOI":"10.1136\/esmoopen-2018-EACR25.762","volume":"3","author":"SM Tsoti","year":"2018","unstructured":"Tsoti, S. M. & Pinato, D. J. AXL receptor tyrosine kinase expression as a prognostic marker and therapeutic target in neuroendocrine tumours. ESMO Open 3, A323 (2018).","journal-title":"ESMO Open"},{"key":"71756_CR43","unstructured":"Klimstra, D. S. et al. WHO Classification of Tumors of the Digestive System 5th edn, Vol. 1 (IARC Press, 2019)."},{"key":"71756_CR44","unstructured":"WHO classification of tumours editorial board. Thoracic tumours. In: WHO Classification of Tumours 5th edn, Vol. 5.6 (IARC Publications, 2021)."},{"key":"71756_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"71756_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European organization for research and treatment of cancer QLQ- C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"71756_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.2012.560","volume":"108","author":"G Yadegarfar","year":"2013","unstructured":"Yadegarfar, G. et al. EORTC Quality of Life Group. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br. J. Cancer 108, 301\u2013310 (2013).","journal-title":"Br. J. Cancer"},{"key":"71756_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/ERC-16-0117","volume":"23","author":"J Cros","year":"2016","unstructured":"Cros, J. et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 23, 625\u2013633 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"71756_CR49","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3727\/096504021X16214197880808","volume":"28","author":"R Della Monica","year":"2022","unstructured":"Della Monica, R. et al. Evaluation of MGMT gene methylation in neuroendocrine neoplasms. Oncol. Res. 28, 837\u2013845 (2022).","journal-title":"Oncol. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71756-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:02:26Z","timestamp":1780966946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71756-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71756"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71756-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. Cives has performed a consultation for Ipsen. Prof. Badalamenti has performed a consultation for Ipsen and has received speaker\u2019s fees from Ipsen. Prof. Porta has performed consultations for Ipsen and Exelixis and has received speaker\u2019s fees from Exelixis. Dr. Tafuto has received grants or consulting fees from Ipsen. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5113"}}